Tesamorelin Peptide: How a Modified GHRH(1-44) Was Built
By The Bionova Club Team
Research use only. This product is supplied for laboratory research use only. It is not intended for human or veterinary use.
Disclosure: Bionova Club sells tesamorelin as a research material, linked below.
Tesamorelin is the full 44-amino-acid sequence of human growth hormone-releasing hormone (GHRH) with one change: a trans-3-hexenoyl group attached to the N-terminal tyrosine. That small acyl cap was added to protect the peptide from a plasma enzyme that clips the first two residues off native GHRH. Everything interesting about tesamorelin, chemically, follows from that design decision.
This article tells the story in order: how GHRH was found, what its receptor looks like, how the native peptide is broken down, and how the developers of TH9507 (the research code for tesamorelin) worked around that weakness.
How this page differs from our comparison: this page covers tesamorelin on its own, from its sequence and receptor to its DPP-IV cleavage and the hexenoyl cap. It does not compare tesamorelin with other peptides. For a side-by-side look at tesamorelin, CJC-1295 and ipamorelin, read our CJC-1295, ipamorelin and tesamorelin comparison.
Tesamorelin at a glance
- What it is: an N-terminally acylated analog of human GHRH(1-44)-NH2
- Research code: TH9507
- Modification: trans-3-hexenoyl group on Tyr1
- Molecular formula: C221H366N72O67S (PubChem CID 16137828)
- Molecular weight: about 5,136 g/mol
- CAS number: 218949-48-5
- Length: 44 residues, C-terminal amide
Where the GHRH sequence came from
The structure of growth hormone-releasing factor came from an unexpected source. In 1982, Guillemin's group isolated a 44-residue peptide with growth hormone-releasing activity from a human pancreatic tumor. They reported that it matched the still-uncharacterized releasing factor in hypothalamic extracts in biological activity (Guillemin et al., 1982).
The peptide had an amidated C-terminus. Its sequence is the backbone of tesamorelin:
YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL-NH2
The same year, the Vale group sequenced the first 39 residues of the factor from a pancreatic islet tumor and proposed alanine as residue 40, with a free acid C-terminus. In their in vitro tests, synthetic hpGRF(1-40)-OH, hpGRF(1-40)-NH2 and hpGRF(1-29)-NH2 showed equivalent activity (Spiess et al., 1982). Later degradation work used both GRH(1-44)-NH2 and GRH(1-40)-OH as native forms of the peptide (Frohman et al., 1989).
The GHRH receptor
A decade after the peptide, the receptor was cloned. Mayo (1992) isolated a rat pituitary cDNA encoding a G protein-coupled receptor with seven transmembrane domains, structurally related to the receptors for secretin and vasoactive intestinal peptide. In the rat, its mRNA was found mainly in the anterior pituitary. The human homolog, when expressed in a cultured cell line, bound GHRH with high affinity and responded with a rise in cyclic AMP.
That result matters for anyone working with analogs. Tesamorelin keeps the native 44-residue chain, so it is designed to engage the same receptor rather than a new target. This is a different design philosophy from the growth hormone secretagogues such as ipamorelin and GHRP-2, which act at a separate receptor; our ipamorelin, GHRP-2 and GHRP-6 comparison explains that second pathway.
Why native GHRH falls apart so quickly
The weak point of native GHRH sits at its very first residues. Frohman et al. (1989) incubated GRH(1-44)-NH2 and GRH(1-40)-OH in plasma and followed the fragments. Their findings, in short:
- Dipeptidylpeptidase IV (DPP-IV) cleaved the bond between residues 2 and 3, removing Tyr-Ala and leaving GRH(3-44)-NH2.
- That cut was blocked by diprotin A, a DPP-IV inhibitor, which pointed to the enzyme responsible.
- Replacing the amino acid at position 1 or 2 with a D-isomer prevented the cleavage.
- A second, trypsin-like cut occurred between residues 11 and 12.
- Overall, DPP-IV was the main route of degradation in plasma.
Because the main cut removes the first two residues, any analog meant to last longer in plasma has to protect that end of the molecule.
The fix: a trans-3-hexenoyl cap on Tyr1
Shortening the chain does not solve the problem. Sermorelin, an earlier research analog, is the first 29 residues (C149H246N44O42S, PubChem CID 16132413), and Frohman's group found that GRH(1-29)-NH2 was also cleaved rapidly at the 2-3 bond. The same study showed that a D-amino acid at position 1 or 2 prevented that cut.
The TH9507 team took a different route. They kept all 44 residues and attached a six-carbon trans-3-hexenoyl group to the alpha-amino group of Tyr1. Ferdinandi et al. (2007) reported that this analog resisted DPP-IV and was degraded more slowly than native hGRF(1-44)NH2 in rat, dog and human plasma in vitro.
From a chemist's point of view, the appeal is that the change is small and sits exactly where the enzyme attacks. The rest of the chain, including the residues the receptor recognizes, is unchanged.
Practical notes for the lab
A few properties of the sequence are worth knowing before you plan an assay:
- It is large. At about 5.1 kDa, tesamorelin is a 44-mer, much bigger than most catalog peptides. Our primer on what peptides are covers how chain length affects handling and analysis.
- It has one methionine. Met27 can oxidize, which shows up as a +16 Da species in mass spectrometry. Keep vials sealed and limit air exposure.
- It carries many basic residues. Arginine and lysine side chains mean the lyophilized solid is normally supplied as a salt. The listed formula describes the free peptide, not the salt. Our guide to acetate vs TFA salt forms explains why that matters for net peptide content.
- Storage: keep the lyophilized material sealed, cold and dry, let it warm to room temperature before opening, and follow the label and batch documentation.
Reading the literature carefully
Most published tesamorelin work comes from the program that developed it. For bench work, the most useful papers are the structural and enzymatic studies cited here, and none of them describes the specific material Bionova supplies. When you compare results across papers, check whether the peptide was used as a free base, acetate or another salt, since that changes how mass relates to moles.
Key takeaways
- Tesamorelin is human GHRH(1-44)-NH2 with a trans-3-hexenoyl group on Tyr1.
- Native GHRH is cut by DPP-IV between residues 2 and 3 in plasma, producing GRH(3-44).
- The hexenoyl cap was designed to block that cleavage while keeping the full native sequence.
- The GHRH receptor is a G protein-coupled receptor related to the secretin and VIP receptors.
- Check salt form and Met27 oxidation when you characterize a batch.
Shop for your research: Tesamorelin 10 mg. Use code CLUB10 at checkout for 10% off.
References
- Guillemin R, Brazeau P, Böhlen P, Esch F, Ling N, Wehrenberg WB. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science. 1982. https://pubmed.ncbi.nlm.nih.gov/6812220/
- Spiess J, Rivier J, Thorner M, Vale W. Sequence analysis of a growth hormone releasing factor from a human pancreatic islet tumor. Biochemistry. 1982. https://pubmed.ncbi.nlm.nih.gov/6295453/
- Mayo KE. Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone. Mol Endocrinol. 1992. https://pubmed.ncbi.nlm.nih.gov/1333056/
- Frohman LA, Downs TR, Heimer EP, Felix AM. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. J Clin Invest. 1989. https://pubmed.ncbi.nlm.nih.gov/2565342/
- Ferdinandi ES, Brazeau P, High K, Procter B, Fennell S, Dubreuil P. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol. 2007. https://pubmed.ncbi.nlm.nih.gov/17214611/
- PubChem. Tesamorelin, CID 16137828. https://pubchem.ncbi.nlm.nih.gov/compound/16137828
- PubChem. Sermorelin, CID 16132413. https://pubchem.ncbi.nlm.nih.gov/compound/16132413
This product is supplied for laboratory research use only. It is not intended for human or veterinary use.
